This HTML5 document contains 134 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n9http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q43250043
rdf:type
wikibase:Item
schema:description
vitenskapelig artikkel naučni članak scientific article published on 2 November 2009 2009 թվականի նոյեմբերի 2-ին հրատարակված գիտական հոդված tudományos cikk 2009年學術文章 2009年學術文章 ২ নভেম্বর ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2009年の論文 artigo científico artículo científico publicado en 2009 2009年学术文章 bài báo khoa học научни чланак teaduslik artikkel 2009年学术文章 מאמר מדעי vitskapeleg artikkel bilimsel makale vedecký článok artikulong pang-agham научна статия scientific article published on 2 November 2009 scienca artikolo artículu científicu espublizáu en 2009 სამეცნიერო სტატია наукова стаття, опублікована в листопаді 2009 2009年學術文章 tieteellinen artikkeli article scientifique 2009年学术文章 artigo científico επιστημονικό άρθρο vetenskaplig artikel 2009년 논문 videnskabelig artikel articolo scientifico 2009年学术文章 vědecký článek บทความทางวิทยาศาสตร์ مقالة علمية نشرت في 2 نوفمبر 2009 мақолаи илмӣ artikull shkencor article científic scientific article published on 2 November 2009 article scientific 2009年學術文章 2009年學術文章 artikel ilmiah wissenschaftlicher Artikel artykuł naukowy artigo científico 2009 nî lūn-bûn 2009年学术文章 articol științific научни чланак wetenschappelijk artikel научная статья 2009年学术文章
p:P577
wds:Q43250043-050E344E-9ABC-4F2F-B48C-D6E78A0BD8B4
wdt:P577
2009-11-02T00:00:00Z
p:P407
wds:Q43250043-83895113-963C-42C6-90B2-0EEAB032424C
wdt:P407
wd:Q1860
p:P2093
wds:Q43250043-834F90E8-6E70-471D-8423-F331A1696924 wds:Q43250043-876318BD-B1E7-41C6-8500-D8D127416835 wds:Q43250043-8DE34F0B-8593-4CB0-B7E2-4CD76D2FBDB4 wds:Q43250043-F5844883-0861-4AC1-8ACA-9717AA30BDE7 wds:Q43250043-AB8BF537-873C-4CC3-B798-82E02000DE21 wds:Q43250043-EDF70834-E291-4674-BB6C-197F9108FAF3 wds:Q43250043-2817A32B-AD4F-42E8-8DE0-50EEDA7DD7FC
wdt:P2093
Hannu Leinonen Tuomo Alanko Seija Ingalsuo Tapio Salminen Kari Möykkynen Mauri Huusko Mika Leinonen
rdfs:label
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
skos:prefLabel
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
schema:name
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
p:P50
wds:Q43250043-A4596E76-4654-4BEC-860D-DA8F4B1F8285 wds:Q43250043-B1FAB517-3B24-47F1-8305-788D6C2546E2 wds:Q43250043-D9352951-E8BC-46E0-A9A0-19793CF80C27 wds:Q43250043-E26BBD9C-7286-4CEB-A517-37E11C50C6EE wds:Q43250043-EED5646B-9FA2-4784-97E6-3503F5B9FCE1 wds:Q43250043-FB18B190-FFF2-4E6D-8E38-6FBD526EF371 wds:Q43250043-239397EF-A5E8-459F-B6E7-3A2FA8AC5A91 wds:Q43250043-341F2011-30BC-4CE1-874D-65DD5BB7E6FB wds:Q43250043-5064CDC6-A4D2-4B61-AD14-C4EE90D12185 wds:Q43250043-56790914-B217-43CE-AADC-784990B6B1A8 wds:Q43250043-6FC34587-9C26-4777-8A78-3EFC21BD6A6B wds:Q43250043-779C72F4-7A01-4D2A-BADC-5819FC6A95C3 wds:Q43250043-8E635BD3-9711-4B28-821A-716BAB952FF8
wdt:P50
wd:Q101210901 wd:Q88043810 wd:Q41600760 wd:Q37069167 wd:Q125317641 wd:Q114522981 wd:Q125317509 wd:Q117249448 wd:Q117249446 wd:Q117249442 wd:Q117249443 wd:Q114337592 wd:Q16299408
p:P1476
wds:Q43250043-861FD17D-3715-42E0-B06D-879F8D2C2DD3
wdt:P1476
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
p:P304
wds:Q43250043-EA15FECB-9F08-4E28-B449-4D9FA889155D
wdt:P304
5685-5692
p:P31
wds:Q43250043-7C46177B-7B83-40F1-B179-6F509751E7E8
wdt:P31
wd:Q13442814
p:P921
wds:Q43250043-11B17CED-F7AB-42F7-A931-01CFBF10F342 wds:Q43250043-F249C6FD-5D4F-48D4-AC76-1CA4491A3874 wds:Q43250043-7641B91A-8E6E-4089-9BAC-FEA6E7F16E62
wdt:P921
wd:Q420436 wd:Q238512 wd:Q412616
p:P698
wds:Q43250043-609BA2F4-F36A-495B-A6C3-5823F2D2BC63
wdtn:P698
n8:19884557
wdt:P698
19884557
p:P1433
wds:Q43250043-4A37A194-3C5E-4C8C-B525-1AD3968A7E74
wdt:P1433
wd:Q400292
p:P433
wds:Q43250043-9B24615D-5CE9-4580-8DAC-3BDD19608BBC
p:P478
wds:Q43250043-53C46B15-3A8E-4352-8432-7D5E06676C7E
wdt:P433
34
wdt:P478
27
p:P356
wds:Q43250043-E1DC0607-93D4-4498-A9BE-1C010A8F0BC0
wdtn:P356
n9:JCO.2008.21.4577
wdt:P356
10.1200/JCO.2008.21.4577